Form 8-K · Current Report · Filed 2025-10-29
Thermo Fisher Scientific to Acquire Clario Holdings, Inc. for $8.875 Billion
Thermo Fisher Scientific Inc. announced on October 29, 2025, the execution of a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for approximately $8.875 billion in cash at the closing of the transaction. The acquisition is expected to be completed by mid-2026, subject to customary closing conditions and regulatory approvals. This strategic acquisition is anticipated to be immediately accretive to Thermo Fisher's Adjusted Earnings Per Share (EPS) and is expected to add $0.45 to adjusted EPS in the first year after the close. The transaction will further strengthen Thermo Fisher's position as a trusted partner to pharma and biotech customers by accelerating innovation and enhancing clinical insights through Clario's industry-leading solutions.
- Filer
- Thermo Fisher Scientific Inc. TMO · NYSE
- Filed
- Accession
- 0000097745-25-000156
- CIK
- 0000097745
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$557.63
Next session
-0.3%
Since filing
+3.0%
Latest close
$574.30
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from TMO reporting the same item, with the next session's move:
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a world-leading biotechnology company that provides essential tools and services for life sciences, biotechnology, pharmaceutical, and healthcare industries. Renowned for its extensive portfolio, the company specializes in offering innovative laboratory products, analytical instruments, and software solutions critical for research, diagnostics, and clinical applications. Thermo Fisher enables scientists to perform complex experiments with cutting-edge technology, from DNA sequencing and cell analysis to clinical diagnostics and specialty chemicals. Serving a vast array of sectors, the company impacts fields such as diagnostics, genetic engineering, and environmental monitoring. Its strategic acquisitions and collaborations strengthen its market presence, making it a go-to partner for scientific advancements and innovation. With operations spanning over 50 countries, Thermo Fisher plays a pivotal role in driving scientific discovery and improving health outcomes globally.
Never miss another TMO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.